<div id="readability-page-1"><h3>President's Day Sale - 70% Off</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li></ul>Sino Biopharmaceutical ( (HK:1177) ) has issued an update. Sino Biopharmaceutical has secured Chinese regulatory approval for a new indication of its Category 1 innovative PD-L1 inhibitor benmelstobart injection, marketed as Andewei, as maintenance therapy after chemoradiotherapy in patients with unresectable stage III non-small cell lung cancer lacking EGFR or ALK alterations. The approval, supported by positive phase III R-ALPS trial data showing significantly prolonged progression-free survival versus placebo and a manageable safety profile, makes benmelstobart the third domestic PD-L1 inhibitor cleared for this setting, strengthening the group’s competitive position in China’s lung cancer market and advancing its strategy to build a diversified oncology pipeline. The most recent analyst rating on (HK:1177) stock is a Hold with a HK$7.90 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page. More about Sino Biopharmaceutical Sino Biopharmaceutical Limited is a Hong Kong-listed pharmaceutical group focused on innovative drug research, development, manufacturing and commercialization, with a strong presence in oncology. The company develops proprietary therapies for the China market, targeting major diseases such as lung cancer with advanced biologic and small-molecule treatments. YTD Price Performance: 5.50% Average Trading Volume: 62,002,447 Technical Sentiment Signal: Buy Current Market Cap: HK$116.6B See more data about 1177 stock on TipRanks’ Stock Analysis page.</div>

520880

159102

512290

Sino Biopharmaceutical has received Chinese regulatory approval for its PD-L1 inhibitor, benmelstobart, for use as maintenance therapy in patients with unresectable stage III non-small cell lung cancer. This approval is based on positive phase III trial results and positions Sino Biopharmaceutical as a strong competitor in China's lung cancer market. The stock currently holds a Hold rating with a price target of HK$7.90. The company focuses on innovative drug development, particularly in oncology, and has a market cap of HK$116.6B.

Tip Ranks

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Huaan Hang Seng Biotech ETF

Guotai CSI Bio-medicine ETF

China Merchants CSI Biotechnology Theme ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC CSI Biotechnology Theme ETF

E Fund CSI Biotechnology Theme ETF

E Fund Hang Seng SCHK Innovative Drug ETF

SINO BIOPHARM

Tianhong CNI BIOMEDICINE ETF

Guotai SSE STAR Brand Name Drug ETF

Sino Biopharm Wins China Nod for New Lung Cancer Use of PD-L1 Drug